Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : EntreMed (ENMD) -- Ignore unavailable to you. Want to Upgrade?

To: DavidCG who wrote (1322)	10/24/1998 10:10:00 PM
From: ACC	Respond to of 2135

DavidCG not yet, i'll know more tomorrow - i think sometime monday morning if they're in the surgical oncology group - ACC

To: DavidCG who wrote (1322)	10/24/1998 10:15:00 PM
From: muddphudd	Read Replies (1) \| Respond to of 2135

To All, Within the last few days I had a conversation with the chief of neurosurgery at Brigham & Women's Hospital. They are teaming up with Folkman (next door at Children's Hospital) to start trials using a viral vector to introduce endostatin/angiostatin into brain tumors (specifically, glioblastomas). The idea is that since Endostatin and Angiostatin have short half-lives, they can overcome this problem by infecting tumor cells with a vector that drives expression of these anti-angiogenesis molecules. Whether it will work, who knows. My impression of gene therapy (which is essentially what this is) is that is far from being a tangible therapeutic vehicle. Nice idea though.